
-
Revolution Medicines Inc NASDAQ:RVMD Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.
Location: 700 Saginaw Dr, California, 94063-4752, US | Website: revolutionmedicines.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.119B
Cash
2.289B
Avg Qtr Burn
-139.4M
Short % of Float
9.42%
Insider Ownership
2.06%
Institutional Own.
-
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RMC-6236 Details Pancreatic ductal adenocarcinoma , Cancer | Phase 3 Data readout | |
RMC-6236 Details Non-small cell lung carcinoma, Cancer | Phase 3 Initiation | |
RMC-5552 (mTORC1 inhibitor) Details Breast cancer, Renal cell carcinoma, Glioblastoma, Solid tumor/s, Cancer | Phase 1b Data readout | |
RMC-4630 + sotorasib Details Non-small cell lung carcinoma, Cancer | Phase 1b Data readout | |
RMC-6291 (KRASG12C) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
RMC-6291+ pembrolizumab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Data readout | |
RMC-9805 (KRASG12D) Details Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma, Cancer | Phase 1 Update | |
RMC-6236 (RASMULTI) Details Solid tumor/s, Pancreatic cancer, Non-small cell lung carcinoma, Cancer | Phase 1 Update | |
RMC-6236 + RMC-6291 Details Solid tumor/s, Cancer | Phase 1 Update | |
RMC-6236+ pembrolizumab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Update | |
RMC-4630 (SHP2 inhibitor) Details Colorectal cancer , Solid tumor/s, Cancer | Failed Discontinued |